@Paperboy2009@JPZaragoza1 Completely agree with that. I think it makes a deal more likely, also considering they would have to start building up a commercial structure for UC now while raising capital has become more difficult at these stock proce levels.
@henwil231@unemon1 Could also be old stuff like templates, drafts, earlier versions that got corrected etc and maybe cannot just be deleted for compliance reasons? Nothing worth speculating about I assume
@unemon1 More patients and more data per patient in the Abtect 3 maintenance, can therefore expect that this takes longer than the 25 days for previous trials.
@Agent0088156721@DenisPaulC Looks like the former resistance at 130$ could now provide some support near term, until the data is published? At least if the stock manages to close the week above that level I have hope.
@smithy05261244@unemon1 Until 10 May, zero searches for Abivax in both countries. Only during the last two weeks. Though as Google states the graph shows relative values, no chance to tell the number of searches.
@torsemide275 The short position has been in place for months. D.E. Shaw has been reducing this short position since April. There’s nothing really new about this information. If only you had Bloomberg... $ABVX